Filing Flows › Nektar Therapeutics (NKTR) › Q2 2026 › vs Q1 2026
Nektar Therapeutics (NKTR) Q2 2026 vs Q1 2026 (quarter over quarter)
Nektar Therapeutics's revenue fell $730K (-7%) from $10.9M in Q1 2026 to $10.1M in Q2 2026.
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $10.1M | $10.9M | −$730K | -7% |
| Other income, net | $1.7M | −$5.8M | $7.5M | — |
| Net loss | $40.6M | $44.9M | −$4.3M | -10% |
| Costs & expenses | $52.5M | $55.8M | −$3.3M | -6% |
| Operating costs | $52.5M | $49.9M | $2.6M | +5% |
| Income tax | $2K | $64K | −$62K | -97% |
| Research & development | $39.1M | $35.7M | $3.4M | +10% |
| General & admin | $12.8M | $13.4M | −$674K | -5% |
| Other operating costs | $578K | $796K | −$218K | -27% |
| Operating cash sources | $79.3M | $47.8M | $31.5M | +66% |
| Depreciation & amortization | $156K | $151K | $5K | +3% |
| Share-based compensation | $3.4M | $3.4M | $10K | +0.3% |
| Cash used in operations | $75.8M | $44.3M | $31.5M | +71% |
| Net loss absorbed | $40.6M | $44.9M | −$4.3M | -10% |
| Working capital & other | $38.7M | $2.9M | $35.8M | 13× |
Questions
How much did Nektar Therapeutics's revenue grow quarter over quarter in Q2 2026?
Nektar Therapeutics's revenue fell $730K (-7%) from $10.9M in Q1 2026 to $10.1M in Q2 2026.